- United Kingdom
- /
- Medical Equipment
- /
- AIM:EMVC
EMV Capital First Half 2024 Earnings: UK£0.071 loss per share (vs UK£0.058 loss in 1H 2023)
EMV Capital (LON:EMVC) First Half 2024 Results
Key Financial Results
- Revenue: UK£1.13m (up 47% from 1H 2023).
- Net loss: UK£1.69m (loss widened by 24% from 1H 2023).
- UK£0.071 loss per share (further deteriorated from UK£0.058 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
EMV Capital Earnings Insights
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom.
Performance of the British Medical Equipment industry.
The company's shares are up 1.9% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 5 warning signs for EMV Capital (of which 2 are concerning!) you should know about.
Valuation is complex, but we're here to simplify it.
Discover if EMV Capital might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:EMVC
EMV Capital
A venture capital firm specializing in seed, growth capital, early and mid stage investments.
Moderate with adequate balance sheet.